Focal low-dose rate brachytherapy for the treatment of prostate cancer

Whole-gland low-dose rate (LDR) brachytherapy has been a well-established modality of treating low-risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs. Focal treatment using LDR brachytherapy has been relatively unexplored, but it may offer...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, William Y, Cohen, Gilad, Yamada, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775638/
https://www.ncbi.nlm.nih.gov/pubmed/24049459
http://dx.doi.org/10.2147/CMAR.S33056
_version_ 1782477402119602176
author Tong, William Y
Cohen, Gilad
Yamada, Yoshiya
author_facet Tong, William Y
Cohen, Gilad
Yamada, Yoshiya
author_sort Tong, William Y
collection PubMed
description Whole-gland low-dose rate (LDR) brachytherapy has been a well-established modality of treating low-risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs. Focal treatment using LDR brachytherapy has been relatively unexplored, but it may offer advantages over other modalities that have established experiences with a focal approach. This is particularly true as prostate cancer is being detected at an earlier and more localized stage with the advent of better detection methods and newer imaging modalities.
format Online
Article
Text
id pubmed-3775638
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37756382013-09-18 Focal low-dose rate brachytherapy for the treatment of prostate cancer Tong, William Y Cohen, Gilad Yamada, Yoshiya Cancer Manag Res Review Whole-gland low-dose rate (LDR) brachytherapy has been a well-established modality of treating low-risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs. Focal treatment using LDR brachytherapy has been relatively unexplored, but it may offer advantages over other modalities that have established experiences with a focal approach. This is particularly true as prostate cancer is being detected at an earlier and more localized stage with the advent of better detection methods and newer imaging modalities. Dove Medical Press 2013-09-13 /pmc/articles/PMC3775638/ /pubmed/24049459 http://dx.doi.org/10.2147/CMAR.S33056 Text en © 2013 Tong et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Tong, William Y
Cohen, Gilad
Yamada, Yoshiya
Focal low-dose rate brachytherapy for the treatment of prostate cancer
title Focal low-dose rate brachytherapy for the treatment of prostate cancer
title_full Focal low-dose rate brachytherapy for the treatment of prostate cancer
title_fullStr Focal low-dose rate brachytherapy for the treatment of prostate cancer
title_full_unstemmed Focal low-dose rate brachytherapy for the treatment of prostate cancer
title_short Focal low-dose rate brachytherapy for the treatment of prostate cancer
title_sort focal low-dose rate brachytherapy for the treatment of prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775638/
https://www.ncbi.nlm.nih.gov/pubmed/24049459
http://dx.doi.org/10.2147/CMAR.S33056
work_keys_str_mv AT tongwilliamy focallowdoseratebrachytherapyforthetreatmentofprostatecancer
AT cohengilad focallowdoseratebrachytherapyforthetreatmentofprostatecancer
AT yamadayoshiya focallowdoseratebrachytherapyforthetreatmentofprostatecancer

Ejemplares similares